search
Back to results

Evaluation of NaproxenSodium and CodeinePhosphate Combination in Osteoarthritis

Primary Purpose

Osteoarthritis

Status
Completed
Phase
Phase 4
Locations
Study Type
Interventional
Intervention
Naproxen Sodium Codeine
Placebo
Sponsored by
Istanbul Medeniyet University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Osteoarthritis focused on measuring Osteoarthritis, NAPROXEN SODIUM

Eligibility Criteria

40 Years - 65 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Clinical and radiological diagnosis of primary osteoarthritis (knee and hip) in the recent year according to criteria of American College of Rheumatology (ACR)
  • Grade 1, 2 or 3 osteoarthritis patients
  • Patients 40 to 65 years of age
  • Patients with WOMAC score ≥ 40
  • Patients with VAS score ≥ 40
  • Patients who signed the consent form

Exclusion Criteria:

  • Grade 4 osteoarthritis patients / Pregnant or breastfeeding mothers
  • Patients with known allergic reaction or intolerance to NSAIDs (nonsteroidal antiinflammatory drugs)
  • Patients hypersensitive to naproxen sodium or codeine
  • Patients who took another analgesic medicine during 24 hours before and/or a nonsteroidal anti-inflammatory medicine during 72 hours before taking study medicine
  • Patients with active gastric or duodenum ulcer
  • Patients with renal dysfunction and/or a kidney disease
  • Patients with severe liver disease
  • Patients with rare hereditary galactose intolerance, Lapp lactase insufficiency or glucose-galactose malabsorption problem
  • Patients with depression treated by a medicine from monoamine oxidase class
  • Patients with uncontrolled hypertension or patients with hypertension that is hardly controlled with medicines
  • Patients with a known medical, psychological disturbance or social status that may negatively affect inclusion into the study or patients who may lead to increase in risk for others with inclusion into the study
  • Patients with proven clinically important and unstable systemic medical disease
  • Patients who have medical contraindication for study medicine
  • Patients who are judged by investigator that they will not adhere or adequately adhere to the study protocol
  • Patients who participated into another study with another study medicine in the last 4 week
  • Patients who intent to donate blood or blood product during the study period or in the following month of the study completion

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Experimental

    Placebo Comparator

    Arm Label

    Naproxen Sodium Codeine

    Placebo

    Arm Description

    One tablet twice a day

    One tablet twice a day

    Outcomes

    Primary Outcome Measures

    Change in Western Ontario Mac Master Questionnaire (WOMAC)
    Change in Visual Analog Scale (VAS)

    Secondary Outcome Measures

    Change in pain severity in all visits after treatment from baseline (VAS)
    Functional effects of combination therapy (WOMAC)
    Change in resting pain after treatment from baseline (WOMAC)
    Change in activity pain after treatment from baseline (WOMAC)
    Change in physical function after treatment from baseline (WOMAC)
    Ratio of rescue medicine use (Rescue medication count)
    Collection of adverse event reports to evaluate safety of the medicine

    Full Information

    First Posted
    July 9, 2015
    Last Updated
    February 24, 2016
    Sponsor
    Istanbul Medeniyet University
    Collaborators
    Abdi Ibrahim Ilac San. ve Tic A.S.
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT02501564
    Brief Title
    Evaluation of NaproxenSodium and CodeinePhosphate Combination in Osteoarthritis
    Official Title
    Randomized, Double-blind and Placebo-controlled Evaluation of Efficacy and Safety of Naproxen Sodium and Codeine Phosphate Combination in Osteoarthritis
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    February 2016
    Overall Recruitment Status
    Completed
    Study Start Date
    May 2013 (undefined)
    Primary Completion Date
    November 2014 (Actual)
    Study Completion Date
    November 2015 (Actual)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Principal Investigator
    Name of the Sponsor
    Istanbul Medeniyet University
    Collaborators
    Abdi Ibrahim Ilac San. ve Tic A.S.

    4. Oversight

    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    Osteoarthritis (OA) pain treatment has limitations in terms of serious adverse effects and low efficacy. The investigators aimed to evaluate efficacy and safety of naproxen sodium/codeine phosphate combination in these patients.
    Detailed Description
    In this prospective, randomized, double blind, placebo controlled clinical trial, 135 patients with osteoarthritis, who were 40-65 years; applied to institution's orthopaedics outpatient clinic; had grade 1, 2, or 3 primary osteoarthritis diagnosed in last 1 year; and had Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) score≥40, and Visual Analogue Scale score≥40,were enrolled. Subjects were randomized (1:1) to placebo (n= 67) or combination (n= 68) arms, in which 550 mg naproxen sodium/30mg codeine phosphate was given orally twice a day for 7 days. Rescue medicine was 500 mg paracetamol (max= 6 tablets/day). Demographic characteristics, medical history, adverse events, VAS and WOMAC scores were collected in study visits performed within 10days.The study was approved by local institutional ethics committee and written informed consents were obtained from all participants.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Osteoarthritis
    Keywords
    Osteoarthritis, NAPROXEN SODIUM

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Phase 4
    Interventional Study Model
    Parallel Assignment
    Masking
    ParticipantInvestigator
    Allocation
    Randomized
    Enrollment
    135 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    Naproxen Sodium Codeine
    Arm Type
    Experimental
    Arm Description
    One tablet twice a day
    Arm Title
    Placebo
    Arm Type
    Placebo Comparator
    Arm Description
    One tablet twice a day
    Intervention Type
    Drug
    Intervention Name(s)
    Naproxen Sodium Codeine
    Other Intervention Name(s)
    Apranax Plus
    Intervention Description
    One tablet twice a day
    Intervention Type
    Drug
    Intervention Name(s)
    Placebo
    Intervention Description
    One tablet twice a day
    Primary Outcome Measure Information:
    Title
    Change in Western Ontario Mac Master Questionnaire (WOMAC)
    Time Frame
    7 days
    Title
    Change in Visual Analog Scale (VAS)
    Time Frame
    7 days
    Secondary Outcome Measure Information:
    Title
    Change in pain severity in all visits after treatment from baseline (VAS)
    Time Frame
    7 days
    Title
    Functional effects of combination therapy (WOMAC)
    Time Frame
    7 days
    Title
    Change in resting pain after treatment from baseline (WOMAC)
    Time Frame
    7 days
    Title
    Change in activity pain after treatment from baseline (WOMAC)
    Time Frame
    7 days
    Title
    Change in physical function after treatment from baseline (WOMAC)
    Time Frame
    7 days
    Title
    Ratio of rescue medicine use (Rescue medication count)
    Time Frame
    7 days
    Title
    Collection of adverse event reports to evaluate safety of the medicine
    Time Frame
    7 days

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    40 Years
    Maximum Age & Unit of Time
    65 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Clinical and radiological diagnosis of primary osteoarthritis (knee and hip) in the recent year according to criteria of American College of Rheumatology (ACR) Grade 1, 2 or 3 osteoarthritis patients Patients 40 to 65 years of age Patients with WOMAC score ≥ 40 Patients with VAS score ≥ 40 Patients who signed the consent form Exclusion Criteria: Grade 4 osteoarthritis patients / Pregnant or breastfeeding mothers Patients with known allergic reaction or intolerance to NSAIDs (nonsteroidal antiinflammatory drugs) Patients hypersensitive to naproxen sodium or codeine Patients who took another analgesic medicine during 24 hours before and/or a nonsteroidal anti-inflammatory medicine during 72 hours before taking study medicine Patients with active gastric or duodenum ulcer Patients with renal dysfunction and/or a kidney disease Patients with severe liver disease Patients with rare hereditary galactose intolerance, Lapp lactase insufficiency or glucose-galactose malabsorption problem Patients with depression treated by a medicine from monoamine oxidase class Patients with uncontrolled hypertension or patients with hypertension that is hardly controlled with medicines Patients with a known medical, psychological disturbance or social status that may negatively affect inclusion into the study or patients who may lead to increase in risk for others with inclusion into the study Patients with proven clinically important and unstable systemic medical disease Patients who have medical contraindication for study medicine Patients who are judged by investigator that they will not adhere or adequately adhere to the study protocol Patients who participated into another study with another study medicine in the last 4 week Patients who intent to donate blood or blood product during the study period or in the following month of the study completion

    12. IPD Sharing Statement

    Learn more about this trial

    Evaluation of NaproxenSodium and CodeinePhosphate Combination in Osteoarthritis

    We'll reach out to this number within 24 hrs